Tripep has received patent protection for administration of ChronVac-C® vaccine using electroporation

Tripep has received patent protection for administration of ChronVac-C® vaccine
using electroporation

Yesterday, Tripep received a patent in the USA for use of the ChronVac-C®
vaccine, administered by several different modalities, including
electroporation, which is the administration technique developed by Inovio and
that Tripep will use together with Inovio in the planned phase I/II trial in
hepatitis C virus infected patients. In addition, the patent covers use of small
fragments of ChronVac-C®, thereby providing a wider protection and a stronger
ChronVac-C® patent portfolio. 

“This patent means an over all protection for Tripep's ChronVac-C® vaccine on
the largest medical market in the world. We are very happy to strengthen the
patent situation for ChronVac-C® in this significant way” says Jan Nilsson, CEO.


ChronVac-C® is a therapeutic vaccine, i.e. it is given to individuals already
infected by the hepatitis C virus with the purpose of halting the infection by
boosting the immune response. Following discussions with the Swedish Medical
Products Agency during the spring 2007, Tripep has decided to start the clinical
development program of ChronVac-C® with a combined phase I/II study in subjects
previously infected with HCV. Phase I/II studies are typically performed in
patients who carry the disease which makes it possible to evaluate potential
side effects, as well as, efficacy of the drug.

Tripep's ChronVac-C® vaccine, administered with Inovio's Medpulser® DDS, has in
an animal model proven to selectively wipe out hepatitis C virus protein
producing liver cells. The total market for therapies against hepatitis C
infections is estimated to over 2 billion dollars 2005 and is expected to grow
to more than 8 billion dollars by 2015 according to Datamonitor. 


For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63
E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .